Standard treatment for muscle-invasive bladder cancer is neoadjuvant chemotherapy followed by radical cystectomy, but more than half of all patients relapse within 3 years. Previous trials of ...

Opens in a new tab or window A personalized strategy of dose-escalated radiotherapy (RT) for bladder cancer had ... 46-52% received neoadjuvant therapy, and 70-71% received radiosensitizing ...

The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

The standard treatment for patients with bladder cancer generally involves chemotherapy, followed by a major surgical procedure known as a radical cystectomy, which involves removing the bladder ...

Rana R. McKay, MD, discusses the significance of clinical trial data for immunotherapy in muscle-invasive bladder cancer (MIBC) treatment she presented at a Case-Based Roundtable event.

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Johnson & Johnson has announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted marketing authorization for BALVERSA®▼ (erdafitinib) as a monotherapy for the treatment ...

Results from a large clinical trial show that treatment with an immunotherapy drug may nearly double the length of time people with high-risk, muscle-invasive bladder cancer are cancer-free ...

The partners are also studying their personalized vaccine with Keytruda as an adjuvant NSCLC treatment for those who haven't gotten neoadjuvant therapy.

Pertuzumab (Perjeta) treats HER2-positive early breast cancer, usually in combination with trastuzumab and chemotherapy. It’s FDA-approved for neoadjuvant and adjuvant treatment. Neoadjuvant use ...